2seventy bio Q2 2023 Earnings Report $2.61 -0.07 (-2.61%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast 2seventy bio EPS ResultsActual EPS-$0.83Consensus EPS -$1.04Beat/MissBeat by +$0.21One Year Ago EPSN/A2seventy bio Revenue ResultsActual Revenue$36.05 millionExpected Revenue$31.81 millionBeat/MissBeat by +$4.24 millionYoY Revenue GrowthN/A2seventy bio Announcement DetailsQuarterQ2 2023Date8/14/2023TimeN/AConference Call ResourcesPress ReleaseTSVT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by 2seventy bio Earnings HeadlinesWeiss Ratings Reiterates Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)February 20 at 3:11 AM | americanbankingnews.comAnalysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $7.20February 18, 2025 | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?February 22, 2025 | Investors Alley (Ad)Citi cuts 2Seventy Bio stock target to $9, maintains Buy ratingFebruary 6, 2025 | msn.com2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial ResultsFebruary 6, 2025 | finance.yahoo.com2seventy bio reports $242 million in 2024 Abecma salesFebruary 6, 2025 | msn.comSee More 2seventy bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email. Email Address About 2seventy bio2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.View 2seventy bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
